TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and

TellBio, Inc., a biotechnology company specializing in cancer detection, has recently published two manuscripts that highlight the potential applications of its TellDx platform in prostate cancer and advanced breast cancer. The papers, titled "DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and circulating tumor cells" and "Modeling the novel SERD elacestrant in cul..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 10.
  • textsms

TellBio Announces Consecutive Manuscripts Demonstrating Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Advanced Breast Cancer

TellBio, Inc., a biotechnology company focused on cancer detection, has recently published two manuscripts that highlight the applications of its TellDx platform in prostate cancer and advanced breast cancer. The publications, titled "DNA hypomethylation silences anti-tumor immune genes in early prostate cancer and circulating tumor cells" and "Modeling the novel SERD elacestrant in cultured ful..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 7. 7.
  • textsms